Acne Fulminans

This publication has 7 references indexed in Scilit:

• Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
  Journal of the American Academy of Dermatology, 2024
• N07 JAKne: JAK inhibitor associated acne, a real-life single-center experience
  Journal of Crohn's and Colitis, 2024
• Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis
  American Journal of Clinical Dermatology, 2023
• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
  The Lancet, 2022
• Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet, 2021
• Activation of Janus kinase signaling pathway in acne lesions
  Dermatologic Therapy, 2020
• Evidence-based recommendations for the management of acne fulminans and its variants
  Journal of the American Academy of Dermatology, 2017